mAbxience | News

mAbxience enters into an agreement with AstraZeneca to produce Covid-19 vaccine


mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico to complete the production and […]

Insud Pharma secures “Excellent” rating in the Profarma programme


The Spanish pharmaceutical group Insud Pharma and its brands Chemo, Exeltis and mAbxience have obtained the “EXCELLENT” rating in the Profarma Plan 2019, in recognition of their industrial activity and their commitment to development and innovation. After four consecutive years of obtaining the “Very Good” rating, this plan, an initiative of the Ministry of Industry, […]

Making available free paediatric medicine can accelerate elimination of congenital Chagas disease


The donation of an essential antiparasitic medicine can potentially accelerate the elimination of Chagas disease infection in children. A pediatric presentation of benznidazole with accurate dosage and will soon be made available freely to address a long-standing gap in the treatment of congenital infections of Chagas disease. The donation, by the Mundo Sano Foundation1 and […]

mAbxience inaugurates new monoclonal antibody biosimilar plant in Argentina


The laboratory mAbxience, which is part of Insud Pharma, has inaugurated a new biosimilar monoclonal antibody plant in Garín, Buenos Aires (Argentina). These drugs are used in the treatment of oncological and autoimmune diseases such as rheumatoid arthritis. With this new plant, the company now has three biosimilar plants, two in Argentina and one in […]

Doctor Silvia Gold awarded Gold Medal by the Royal Academy of Medicine and Surgery of Murcia


•This award is recognition of the hard work and dedication of Silvia Gold, President of the Mundo Sano Foundation, in changing the course of Chagas disease. •Mundo Sano is currently running the campaign Not a Single Baby with Chagas, to ensure that all babies and women of reproductive age have access to diagnosis and treatment. […]

Mundo Sano launches “Not a Single Baby with Chagas” initiative to change the history of Chagas disease


“Not a Single Baby with Chagas” is a reflection of the Foundation’s commitment to ensuring that by 2030 all babies born with Chagas disease can be treated and cured, and that all women of reproductive age have access to diagnosis and treatment. Every hour, a baby is born somewhere in the world with Chagas disease. […]

A 3D-printed human skin dressing, a migraine predictor and a smart insulin pen: the three startups selected for support by Insud Pharma


BioDan, a 3D dressing derived from human skin which can be bioprinted and frozen, Brainguard, a wearable system that predicts migraines, and Insulclock, a system which monitors and controls the treatment of diabetes patients are the three startups selected in the second round of the ChemoStart accelerator programme, which seeks to support innovative, disruptive solutions […]

Twelve startups present disruptive healthcare solutions at Insud Pharma’s Pitch Day


• The ChemoStart Programme is an initiative by Insud Pharma, spearheaded by Leandro Sigman, to support innovative healthcare startups   • In the second edition of the programme, 12 finalists have been shortlisted to present to a panel of experts at the Pitch Day on Thursday 31 January Madrid, 30 January 2019.- Insud Pharma’s startup […]

Publication of the final data from the clinical trial for mAbxience bevacizumab in metastatic colorectal cancer published in The Lancet Gastroenterology & Hepatology


The prestigious scientific journal The Lancet Gastroenterology and Hepatology journal has published the results of the comparative study of pharmacokinetics, efficacy, safety and immunogenicity of bevacizumab biosimilar BEVZ92 in combination with FOLFOX or FOLFIRI, as the first-line treatment for metastatic colorectal cancer versus the original reference product.  The trial included 15 sites from 5 countries, […]

Insud Pharma secures “very good” rating in the Profarma Programme


mAbxience and the entire Insud Pharma group have once again been rated “very good” in the 2017-2020 edition of the Spanish government’s Profarma Programme, thanks to our contribution to modernising the sector, our commitment to R&D and our clear focus on activities that add value. The Programme is run by the Spanish Ministry of Economy, […]